2021/7/19 – CRI Report

Investigation Report on China’s Caspofungin Market 2021-2025

admin — Mon, 19 Jul 2021 02:43:42 +0000

Caspofungin is the first echinocandin antifungal drug. It has a broad antibacterial spectrum, a long half-life, a high binding rate to human serum proteins, and a few adverse reactions. It is known as the trump card in the systemic antifungal drug market. The drug is an anti-fungal infection drug currently recommended by clinical guidelines in various countries and is widely marketed worldwide. Caspofungin was originally developed by Merck Sharp & Dohme. It was launched in the United States and Europe in 2001. It was launched in China under the trade name CANCIDAS in 2002. By 2020, Caspofungin has been included in China’s Class B medical insurance. There are 4 manufacturers in the Chinese market in 2020, which are Merck Sharp & Dohme (IA) Corp, Merck Sharp & Dohme Ltd, Jiangsu Hengrui Medicine Co., Ltd., and Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

According to CRI’s market research, the sales value of Caspofungin in the Chinese market increased year by year from 2016 to 2019. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of Caspofungin in the Chinese market decreased to CNY 801 million in 2020 and the CAGR of Caspofungin in sales value from 2016 to 2020 is 15.45%.

CRI expects that with the relief of COVID-19, the sales of Caspofungin in the Chinese market will have a restorative growth from 2021 to 2025. In addition, Caspofungin has the characteristics of broad antifungal spectrum, excellent curative effect and high safety. Based on these advantages, the sales value and sales volume of Caspofungin in the Chinese market still has room to rise. By the first half of 2021, in addition to the original research companies, a total of 5 domestic companies have been approved, including Huadong Medicine Co.,Ltd., Borui Pharmaceutical Technology Development Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Haisco Pharmaceutical Group Co., Ltd. It is expected that with the addition of new manufacturers, the sales value of Caspofungin will continue to rise.

Topics Covered:

-The impact of COVID-19 on China’s Caspofungin market
– Sales value of China’s Caspofungin 2016-2020
– Competitive landscape of China’s Caspofungin market
– Prices of Caspofungin in China
– Prices of Caspofungin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Caspofungin market
– Prospect of China’s Caspofungin market from 2021 to 2025

The post Investigation Report on China’s Caspofungin Market 2021-2025 first appeared on CRI Report.

Investigation Report on China’s Pregabalin Market 2021-2025

admin — Mon, 19 Jul 2021 02:43:42 +0000

China’s Pregabalin market size increased year by year from 2016 to 2020, according to CRI’s research. Among them, the growth in sales value in 2019 was the most obvious. The sales value of Pregabalin reached CNY143 million in 2019, with an annual growth rate of 57.19%. The main reason is that Pregabalin was approved for new indications in China from 2018 to 2019, and the NMPA lifted the restriction on Pregabalin medical insurance indications in 2019, which led to a substantial increase in its sales volume and sales value.

In 2020, the sales value of Pregabalin in the Chinese market is approximately CNY186 million. The CAGR in sales value of Pregabalin from 2016 to 2020 is 40.55%.

Pregabalin is an ion channel modulator used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its product, LYRICA was originally developed by Pfizer Ltd. LYRICA was launched in China in 2010 and was approved for the treatment of post-herpetic neuralgia. In 2018, it was approved for fibromyalgia indication. Subsequently, some generic drugs of Pregabalin were launched in China one after another.

In 2019, Pregabalin (trade name: Laireike) produced by Chongqing Saiwei Pharmaceutical was approved for the treatment of adult partial epilepsy, adding a new indication for Pregabalin in the Chinese market. By 2020, Pregabalin has been included in China’s Class B medical insurance, and there are three manufactures in the Chinese market, of which Pfizer Ltd is the main manufacture.

CRI expects that with the addition of new companies, the sales volume and market scale of Pregabalin in the Chinese market will continue to expand from 2021 to 2025. According to CRI’s market research, by the first half of 2021, there are more than 20 companies in China that are applying for Pregabalin generic drugs, including Jiangsu Hengrui Pharmaceutical Co., Ltd., Xuzhou Enhua Pharmaceutical Co., Ltd., and Sichuan Kelun Pharmaceutical Co., Ltd. In addition, China has approved the marketing of 3 indications of Pregabalin, and a total of 4 indications have been approved for marketing globally. Therefore, the number of indications of Pregabalin in China is likely to increase, and sales value and sales volume will increase in the future.

Topics Covered in Investigation Report on China’s Pregabalin Market 2021-2025

-The impact of COVID-19 on China’s Pregabalin market
– Sales value of China’s Pregabalin 2016-2020
– Competitive landscape of China’s Pregabalin market
– Prices of Pregabalin in China
– Prices of Pregabalin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Pregabalin market
– Prospect of China’s Pregabalin market from 2021 to 2025

Investigation Report on Chinese Pregabalin Market, 2020-2024

The post Investigation Report on China’s Pregabalin Market 2021-2025 first appeared on CRI Report.

Investigation Report on China’s Tigecycline Market 2021-2025

admin — Mon, 19 Jul 2021 02:43:42 +0000

Tigecycline is a broad-spectrum glycyl cyclic peptide antibiotic administered intravenously. Tigecycline is approved for complicated skin and skin structure infections or complicated intra-abdominal infections patients aged 18 and over. These infections include complicated appendicitis, burn infection, intra-abdominal abscess, deep soft tissue infection and ulcer infection. Tigecycline was developed by Wyeth Corporation of the United States and was listed in China under the trade name TYGACIL in 2011. Subsequently, some generic drugs from local Chinese companies were listed. By 2020, tigecycline has been included in China’s Class B medical insurance, and there are several manufacturers in the Chinese tigecycline market.

According to CRI’s market research, the sales value of tigecycline in the Chinese market increased year by year at a compound annual growth rate of 43.45% from 2016 to 2019. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of tigecycline in the Chinese market decreased to CNY 885 million in 2020 and the CAGR of tigecycline sales value from 2016 to 2020 is 28.64%.

CRI expects that the sales value of tigecycline in the Chinese market will have a restorative growth from 2016 to 2020 with the relief of COVID-19. According to the latest set of data disclosed by the World Health Organization, 700,000 people worldwide die each year due to “super bacteria” infection, and 230,000 newborns die prematurely because of this. It can be estimated that by 2050, the number of deaths may exceed 10 million. Therefore, the sales value and sales volume of tigecycline against “super bacteria” such as methicillin-resistant Staphylococcus aureus (MRSA) will continue to rise. By the first half of 2021, the new indication for tigecycline in the Chinese market-community and hospital-acquired pneumonia is under review. It can be expected that with the increase in new indications in the future, the sales value and sales volume of tigecycline have room to rise.

Topics Covered:

-The impact of COVID-19 on China’s Tigecycline market
– Sales value of China’s Tigecycline 2016-2020
– Competitive landscape of China’s Tigecycline market
– Prices of Tigecycline in China
– Prices of Tigecycline in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Tigecycline market
– Prospect of China’s Tigecycline market from 2021 to 2025

The post Investigation Report on China’s Tigecycline Market 2021-2025 first appeared on CRI Report.

Investigation Report on China’s Capecitabine Market 2021-2025

admin — Mon, 19 Jul 2021 02:43:41 +0000

Capecitabine is a pyrimidine analog (pentoxycarbonyl-deoxy-cytosine nucleoside) that has anti-tumor activity to inhibit a variety of solid tumors, including breast and colon cancer. Capecitabine was developed by Roche. Its product, XELODA was approved to enter the Chinese market in 2001. By 2020, there are several manufacturers in the Capecitabine market in China.

According to CRI’s market research, the sales of Capecitabine in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the COVID-19 pandemic on the hospital’s overall diagnosis and treatment services, sales in 2020 decreased to CNY 914 million, a year-on-year decrease of 9.31%. The CAGR of Capecitabine sales in the Chinese market from 2016 to 2020 is 1.21%.

CRI expects that with the easing of the COVID-19 pandemic, the sales of Capecitabine in the Chinese market will have a restorative growth in 2021-2025. In 2020, the number of COVID-19 breast cancers worldwide reached 2.26 million, and the number of colon cancers reached 1.93 million, both of which were on the rise. The number of breast and colon cancers in China will be also on the rise in the future. Therefore, the sales volume of Capecitabine, which is used to inhibit the anti-tumor activity of a variety of solid tumors, will increase with the increase in the number of breast cancer and colon cancer patients in China. There is also room for sales to rise. In addition, by the end of 2020, a number of companies led by Chengdu Yuandong Biopharmaceuticals have already reported for Capecitabine generic drug approval. In the next few years, more manufacturers will join the Chinese market. The sales volume and sales of Capecitabine in China are expected to rise.

Topics Covered:

-The impact of COVID-19 on China’s Capecitabine market
– Sales value of China’s Capecitabine 2016-2020
– Competitive landscape of China’s Capecitabine market
– Prices of Capecitabine in China
– Prices of Capecitabine in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Capecitabine market
– Prospect of China’s Capecitabine market from 2021 to 2025

The post Investigation Report on China’s Capecitabine Market 2021-2025 first appeared on CRI Report.

Investigation Report on China’s Linezolid Market 2021-2025

admin — Mon, 19 Jul 2021 02:43:41 +0000

Linezolid is an oxazolidinone antibiotic, mainly used to treat infections caused by gram-positive (G+) cocci, including suspected or confirmed hospital-acquired pneumonia (HAP) caused by methicillin-resistant Staphylococcus aureus (MRSA), community-acquired pneumonia (CAP), complex skin or skin and soft tissue infections (SSTI), and vancomycin-resistant enterococcus (VRE) infections. Linezolid’s product ZYVOX was developed by Pfizer Pharmaceuticals. It was approved to enter the Chinese market in 2006. Since then, some generic drugs have also been listed in the Chinese market. According to CRI’s market research, by 2020, there are several manufacturers besides Pfizer in the Linezolid market in China.

According to CRI’s market research, the sales value of Linezolid in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Linezolid in the Chinese market fell to CNY695 million in 2020, a year-on-year decrease of 14.89%. However, the CAGR of Linezolid sales value in the Chinese market from 2016 to 2020 is still 14.45%.

CRI expects that with the relief of COVID-19, the sales value of Linezolid in the Chinese market will have a restorative growth from 2021 to 2025. In addition, Linezolid has high antibacterial activity against Staphylococcus, Streptococcus pneumoniae, and Enterococcus bacteria, and has no cross-resistance with other antibacterial drugs. It is currently the first choice for the treatment of severe infections such as septic shock. These advantages make sales value and sales volume have room to rise.

Topics Covered:

-The impact of COVID-19 on China’s Linezolid market
– Sales value of China’s Linezolid 2016-2020
– Competitive landscape of China’s Linezolid market
– Prices of Linezolid in China
– Prices of Linezolid in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Linezolid market
– Prospect of China’s Linezolid market from 2021 to 2025

The post Investigation Report on China’s Linezolid Market 2021-2025 first appeared on CRI Report.

Investigation Report on China’s Octreotide Market 2021-2025

admin — Mon, 19 Jul 2021 02:43:41 +0000

Octreotide is a derivative of artificially modified natural somatostatin, which is an octapeptide. Its physiological effects include inhibiting growth hormone function, inhibiting the secretion of gastric acid, pancreatic enzymes, glucagon and insulin, reducing visceral blood flow, reducing gastrointestinal motility, etc. It is clinically used for emergency treatment of esophageal-varices bleeding, treatment of acromegaly and treatment related to gastrointestinal endocrine tumors. Its product SANDOSTATIN was developed by Novartis Pharma Schweiz AG and was approved to enter the Chinese market in 2003. Since then, some generic drugs have also been listed in the Chinese market. By 2020, there are several manufacturers in the Chinese Octreotide market, among which Novartis Pharma Schweiz AG accounts for the most market share.

According to CRI’s market research, the sales value of Octreotide in the Chinese market from 2016 to 2019 were relatively stable. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Octreotide in the Chinese market decreased to CNY690 million, a year-on-year decrease of 3.8%. From 2016 to 2020, the CAGR of Octreotide sales value in the Chinese market is -0.48%.

CRI expects that with the relief of COVID-19, the sales value of Octreotide in the Chinese market will have a restorative growth from 2021 to 2025. In addition, compared with similar drugs, Octreotide has a longer action time, not only can extensively inhibit the secretion of digestive juice, but also promotes the absorption of digestive juice by the intestinal mucosa. Based on these advantages, the sales value and sales volume of Octreotide still has room to rise. At the same time, in recent years, the pace of life of Chinese residents has accelerated, and irregular eating habits have increased the prevalence of various gastrointestinal diseases. Therefore, the demand for Octreotide will continue to expand and its sales value will continue to grow from 2021 to 2025.

Topics Covered:

-The impact of COVID-19 on China’s Octreotide market
– Sales value of China’s Octreotide 2016-2020
– Competitive landscape of China’s Octreotide market
– Prices of Octreotide in China
– Prices of Octreotide in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Octreotide market
– Prospect of China’s Octreotide market from 2021 to 2025

The post Investigation Report on China’s Octreotide Market 2021-2025 first appeared on CRI Report.

Investigation Report on China’s Hemocoagulase Market 2021-2025

admin — Mon, 19 Jul 2021 02:43:41 +0000

Hemocoagulase, developed by Swiss Sugo Pharmaceuticals, is a high-purity, single-component hemagglutinin clinical hemostatic drug. Its original drug is called REPTILASE, which is not on the market in China. In 2009, Hemocoagulase was firstly launched in China. Its product, Suling was developed by Beijing Kangchen Pharmaceutical Co., Ltd. Since then, some generic drugs have also been listed in the Chinese market. According to CRI’s market research, there are 4 manufacturers in the Chinese Hemocoagulase market by 2020, among which Beijing Kangchen Pharmaceutical Co., Ltd. accounts for the most market share.

According to CRI’s market research, the sales value of Hemocoagulase in the Chinese market is relatively stable from 2016 to 2019. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Hemocoagulase in the Chinese market fell to CNY694 million in 2020, a year-on-year decline of 32%. The CAGR of Hemocoagulase sales value in the Chinese market from 2016 to 2020 is -11.05%.

CRI expects that with the relief of COVID-19, the sales value of Hemocoagulase in the Chinese market will have a restorative growth from 2021 to 2025. In addition, the Hemocoagulase injection is targeted, which cannot cause hypercoagulability in the blood. Based on this advantage, the sales value and sales volume of Hemocoagulase have a certain room for growth. At the same time, in the first half of 2021, China introduced a policy to encourage each couple to have three children. With the help of a new round of “baby boom” that may come, China’s procoagulant hemostatic drugs have a better market prospect, and sales value of Hemocoagulase are expected to be on the rise from 2021 to 2025.

Topics Covered:

-The impact of COVID-19 on China’s Hemocoagulase market
– Sales value of China’s Hemocoagulase 2016-2020
– Competitive landscape of China’s Hemocoagulase market
– Prices of Hemocoagulase in China
– Prices of Hemocoagulase in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Hemocoagulase market
– Prospect of China’s Hemocoagulase market from 2021 to 2025

The post Investigation Report on China’s Hemocoagulase Market 2021-2025 first appeared on CRI Report.

Investigation Report on China’s Iohexol Market 2021-2025

admin — Mon, 19 Jul 2021 02:43:41 +0000

Iohexol is a non-ionic X-ray contrast agent. Iohexol injection is suitable for intravascular and intracavitary injections in adults and children. In clinical angiography (cerebrovascular angiography, coronary angiography, peripheral and visceral angiography, ventricle angiography), CT-enhanced imaging of the head and body , Intravenous urography (IVP), arthrography, endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), hernia or fistula angiography, gastrointestinal angiography, “T “Pipeline radiography and so on. Iohexol was developed by Nycomed and was approved to enter the Chinese market in 1997. Since then, some generic drugs have also been listed in the Chinese market. According to CRI’s market research, there are several suppliers in the Chinese Iohexol market by 2020, of which Yangtze River Pharmaceutical Group Co., Ltd. accounts for the most market share.

According to CRI’s market research, the sales value of Iohexol in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of COVID-19 on the hospital’s overall diagnosis and treatment services, its sales value of Iohexol in the Chinese market decreased to CNY691 million, a year-on-year decrease of 13.53%. The CAGR of Iohexol sales value in the Chinese market from 2016 to 2020 is 0.45%.

CRI expects that with the relief of COVID-19, the sales of Iohexol in the Chinese market will have a restorative growth from 2021 to 2025. With the popularization of medical services in China and the advancement of medical technology, the demand for iodine and a non-ionic X-ray contrast agent in Chinese medical industry has gradually expanded, and sales value are expected to continue to grow from 2021 to 2025.

Topics Covered:

-The impact of COVID-19 on China’s Iohexol market
– Sales value of China’s Iohexol 2016-2020
– Competitive landscape of China’s Iohexol market
– Prices of Iohexol in China
– Prices of Iohexol in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Iohexol market
– Prospect of China’s Iohexol market from 2021 to 2025

The post Investigation Report on China’s Iohexol Market 2021-2025 first appeared on CRI Report.

Investigation Report on China’s Metformin Market 2021-2025

admin — Mon, 19 Jul 2021 02:43:41 +0000

Metformin is the first-line drug for the treatment of type 2 diabetes, especially in people who are overweight. Metformin was originally developed by Merck Sharp & Dohme (trade name: GLUCOPHAGE ). GLUCOPHAGE first went on the market in France in 1957 and went on the market in China in 1994. Since then, some generic drugs have also been listed in the Chinese market. According to CRI’s market research, there are several manufactures in China’s Metformin market by 2020, of which Sino-US Shanghai Squibb Pharmaceutical Co., Ltd. accounts for the most market share.

According to CRI’s market research, the sales value of Metformin in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of COVID-19 on the overall medical diagnosis and treatment services, the sales value of Metformin in the Chinese market fell to CNY707 million in 2020, a year-on-year decline of 4.19%. The CAGR of Metformin sales value in the Chinese market from 2016 to 2020 is 7.01%.

CRI expects that with the relief of COVID-19, the sales value of Metformin in the Chinese market will have a restorative growth from 2021 to 2025. In addition, the number of diabetic patients in China ranks first in the world. The total prevalence rate of diabetes in adults is 12.8%. Type II diabetes accounts for 90% of diabetic patients, and the number of patients is huge. At the same time, as the population ageing in China is becoming increasingly severe, the number of patients and the prevalence rate are also increasing year by year. Therefore, the sales volume and sales value of Metformin for the treatment of type 2 diabetes have an increasing trend. In addition, compared with similar drugs, Metformin not only has the effect of lowering blood sugar, but also may have the effect of weight loss and treatment of hyperinsulinemia, and it can be effective for patients with poor efficacy of certain sulfonylureas. Based on these advantages, it is expected that the sales value of Metformin in the Chinese market will increase from 2021 to 2025.

Topics Covered:

-The impact of COVID-19 on China’s Metformin market
– Sales value of China’s Metformin 2016-2020
– Competitive landscape of China’s Metformin market
– Prices of Metformin in China
– Prices of Metformin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Metformin market
– Prospect of China’s Metformin market from 2021 to 2025

The post Investigation Report on China’s Metformin Market 2021-2025 first appeared on CRI Report.

Investigation Report on China’s Nifedipine Market 2021-2025

admin — Mon, 19 Jul 2021 02:43:41 +0000

Nifedipine is a dihydropyridine calcium channel blocker, which is mainly used to bind to L-type calcium channels. Nifedipine is mainly used to treat chronic stable angina pectoris, vasospasm angina pectoris (angina pectoris, variant angina pectoris) and essential hypertension. Nifedipine was developed by Bayer AG, and Bayer AG’s Nifedipine is traded under the name ADALAT. By 2020, there are several manufacturers in China’s Nifedipine market, among which Bayer AG has the highest market share in sales value.

According to CRI’s market research, the sales value of Nifedipine in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of Covid-19 on the overall medical diagnosis and treatment services, the sales value of Nifedipine in the Chinese market fell to CNY730 million, and the CAGR of Nifedipine from 2016 to 2020 was 4.42%.

CRI expects that with the relief of Covid-19, the sales value of Nifedipine in the Chinese market will have a restorative growth from 2021 to 2025. In addition, in recent years, nearly 20 million people worldwide died of cardiovascular and cerebrovascular diseases caused by hypertension and coronary heart disease each year. An estimated 300 million patients live with high blood pressure in China. As ageing of population in China becomes increasingly severe, the number and prevalence of patients are increasing year by year. Therefore, there is an increasing trend in sales volume of Nifedipine for the treatment of angina and hypertension. At the same time, compared with similar drugs, Nifedipine has longer action time, fewer doses, more stable blood concentrations, and less toxic and side effects. Based on these advantages, the sales volume and sales value of Nifedipine in the Chinese market will continue to grow from 2021 to 2025.

Topics Covered:

-The impact of COVID-19 on China’s Nifedipine market
– Sales value of China’s Nifedipine 2016-2020
– Competitive landscape of China’s Nifedipine market
– Prices of Nifedipine in China
– Prices of Nifedipine in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Nifedipine market
– Prospect of China’s Nifedipine market from 2021 to 2025

The post Investigation Report on China’s Nifedipine Market 2021-2025 first appeared on CRI Report.